People · Operator
Named in public records as an officer, director or promoter · active 2009–2010 · Pharmaceuticals, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| China Medicine Corp | — | Pharmaceuticals | Series C | $69.6M | $2.4B | 2010 |
| China Biologic Products, Inc. | — | Pharmaceuticals | Series A | $9.6M | $295.9M | 2009 |
| Yongye Biotechnology International, Inc. | — | Other | Series A | $9.0M | $136.0M | 2009 |
Sean Shao at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sean Shao on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Robert Adler | 1 | 3 |
| Robert Lu | 1 | 2 |
| Senshan Yang | 1 | 1 |
| Daniel Shih | 1 | 1 |
| Ryan Shih | 1 | 1 |
| Ian Grant Robinson | 1 | 1 |
| Rachel Gong | 1 | 1 |
| Yangfang Chen | 1 | 1 |
| Siu Ling Chan | 1 | 1 |
| Chao Ming Zhao | 1 | 1 |
| Jie Gan | 1 | 1 |
| Tong Jun Lin | 1 | 1 |
| Ling Lin Li | 1 | 1 |
| Yun-Yun Tristan Kuo | 1 | 1 |
| Li Xindan | 1 | 1 |
| Zishen Wu | 1 | 1 |
| Zhang Rijun | 1 | 1 |
| Sun Taoran | 1 | 1 |
| Gilmore Larry | 1 | 1 |
| Sam Yu | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.